<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783870</url>
  </required_header>
  <id_info>
    <org_study_id>F-2020-3604-035</org_study_id>
    <nct_id>NCT04783870</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozin on LV Remodeling Post AMI</brief_title>
  <official_title>Effect of Dapagliflozin on Left Ventricular Remodeling in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall hypothesis of the study is that Dapagliflozin will reduce left ventricular&#xD;
      remodeling in patients who have had a myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with heart failure, with or without diabetes, SGLT2i have shown to decrease&#xD;
      remodeling. However, this has not been tested in patients following an acute myocardial&#xD;
      infarction.&#xD;
&#xD;
      Acute myocardial infarction is serious condition with increasing incidence across the world.&#xD;
      Following treatment, a reasonable amount of patients develop remodeling of the left&#xD;
      ventricle, which is associated with worse prognosis. This occurs despite patients are treated&#xD;
      with GDMT.&#xD;
&#xD;
      Dapagliflozin is an SGLT2i with biological plausibility to decrease left ventricular&#xD;
      remodeling following acute myocardial infarction. In the present study, researchers will test&#xD;
      the hypothesis that Dapagliflozin will reduce left ventricular remodeling in patients who&#xD;
      have had a myocardial infarction (less than 7 days). This will be a randomized, single-blind,&#xD;
      placebo controlled trial. The primary endpoint will be the change in end-diastolic and&#xD;
      end-systolic left ventricular volumes from baseline to the end of the intervention (6&#xD;
      months). We will include patients with acute myocardial infarction who have been treated with&#xD;
      primary PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants will receive either Dapagliflozin or Placebo. They will not know which arm they have been allocated to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular remodeling</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in end-diastolic and end-systolic left ventricular volumes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Natriuretic peptides</measure>
    <time_frame>6 months</time_frame>
    <description>Change in natriuretic peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed with KCCQ</measure>
    <time_frame>6 months</time_frame>
    <description>Change in quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg PO QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo PO QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin 10 mg PO QD</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction treated within the 24 hours of beginning of symptoms&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  SBP &gt; 90 mmHg&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Glomerular Filtration Rate &lt; 30 ml/min/1.73 m2.&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Cancer or life-threatening condition&#xD;
&#xD;
          -  Use of continuous parental inotropic agents&#xD;
&#xD;
          -  Psychiatric disease incompatible with being in study.&#xD;
&#xD;
          -  Any contraindication to MRI procedures.&#xD;
&#xD;
          -  Any other medical or physical condition considered to be inappropriate by a study&#xD;
             physician&#xD;
&#xD;
          -  Scheduled for a PCI or CABG within the next 6 months&#xD;
&#xD;
          -  Hemodynamic unstability&#xD;
&#xD;
          -  Currently on any SGLT2i&#xD;
&#xD;
          -  One or more episodes of severe hypoglicemia&#xD;
&#xD;
          -  Acute urinary or genital infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan B Ivey-Miranda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Almeida-Gutierrez, MD</last_name>
    <phone>+52 5556276900</phone>
    <phone_ext>22007</phone_ext>
    <email>eduardo.almeida@imss.gob.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Cardiología, Centro Médico Nacional Siglo XXI</name>
      <address>
        <city>Ciudad de México</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan B Ivey-Miranda, MD</last_name>
      <phone>+52 5543683768</phone>
      <email>betuel.ivey@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Mexicano del Seguro Social</investigator_affiliation>
    <investigator_full_name>Eduardo Almeida Gutiérrez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared only to researches with extensive research. These will be analyzed on case-by-case basis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After the study termination</ipd_time_frame>
    <ipd_access_criteria>IPD will be shared only to researches with extensive research. These will be analyzed on case-by-case basis.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

